Progress in antifungal therapy: Echinocandins versus azoles

The arrival of the echinocandin class of antifungals was heralded as a major advance in the therapy of patients with opportunistic fungal infections. Together with expanded numbers of azole agents, clinicians now have a generous selection of antifungals. The present review compares the spectrum of activity, pharmacokinetic and safety data for echinocandins and azoles and discusses the current clinical roles of each class.

Section editors:Gary Woodnutt – CovX, San Diego, USAPaul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland